Inferra AIResearch Tools

Inferra AI / Company / BBIO

Bridgebio Pharma, Inc.

BBIO · Health Care

Last earnings Oct 29, 2026

Key results

Revenuequarter

$353.2 million

htm EX-99.1 Document Exhibit 99.1 BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates - $353.2 million in total third quarter revenues, primarily comprised of $253.2 million of U.

SEC original ↗Bridgebio Pharma, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Attruby net product revenue (up approximately $31 million sequentially and $145 million year over year).

SEC original ↗Bridgebio Pharma, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Loss from operations was $11.6 million, driven by increased revenue and a one-time $75.0 million BEYONTTRA sales milestone from Bayer.

SEC original ↗Bridgebio Pharma, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Attruby net product revenue, $0.1 million of Rest of World Attruby net product revenue, $20.5 million from royalty revenue, and $79.3 million in license and services revenue.

SEC original ↗Bridgebio Pharma, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Revenueytd

$105.0 million

This decrease was primarily due to recognition of $105.0 million of regulatory milestone-related revenues during the nine months ended September 30, 2025, partially offset by recognition of a $75.0 million sales milestone under the Bayer License Agreement achieved during the third quarter of 2026.

SEC original ↗Bridgebio Pharma, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

The $98.9 million increase was primarily driven by a $63.2 million increase in selling, general and administrative (SG A) expenses, reflecting continued investment in both the ongoing commercialization of Attruby and the pre-commercial activities for BridgeBio's late-stage product candidates, a $30.6 million increase in research and development (R D) expenses to support the development of late-stage product candidates, and a $13.9 million increase in total cost of revenues primarily due to higher sales volume of Attruby.

SEC original ↗Bridgebio Pharma, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

The $284.3 million increase was primarily driven by a $177.9 million increase in SG A expenses, reflecting continued investment in both the ongoing commercialization of Attruby and the pre-commercial activities for BridgeBio's late-stage product candidates, an $84.1 million increase in R D expenses to support the development of late-stage product candidates, and a $32.6 million increase in total cost of revenues primarily due to higher sales volume of Attruby.

SEC original ↗Bridgebio Pharma, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

AI analysis

Q3 2026 · reported Oct 29, 2026

Based on: Earnings release + parent 8-K — transcript not held

Revenue · Q3 2026
$353.2M
EX-99 · Oct 29, 2026

Headline figures

MetricQ3 2026Prior qtrYear ago
Revenue$353.2 million$243.7 million—

EX-99 · Oct 29, 2026

Guidance · company-stated

No guidance located in the held release

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

These changes were partially offset by a $21.2 million decrease in loss on extinguishment of debt recognized in the first quarter of 2025, a $19.5 million decrease in net loss from equity method investments, and a $10.5 million increase in interest income.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates - $353.2 million in total third quarter revenues, primarily comprised of $253.2 million of U.S

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

No guidance located in the held release

Capital allocation

These changes were partially offset by a $21.2 million decrease in loss on extinguishment of debt recognized in the first quarter of 2025, a $19.5 million decrease in net loss from equity method investments, and a $10.5 million increase in interest income.

SEC original ↗Bridgebio Pharma, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Strategy & priorities

The first participant was dosed in ASCEND-ATTR, the Phase 3b 4 study to prospectively test disease reversal with Attruby - BBP-418 for LGMD2I R9 has a November 27, 2026 PDUFA date, with Priority Review.

SEC original ↗Bridgebio Pharma, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Based on interactions with EU national health authorities, the Company intends to submit an MAA to the EMA in the first half of 2028 - Oral infigratinib for achondroplasia has a February 4, 2027 PDUFA date, with Priority Review.

SEC original ↗Bridgebio Pharma, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

In hypochondroplasia, the Phase 2 3 ACCEL study is expanding to higher doses to find the optimal dose, supported by safety data from PROPEL 3 and PROPEL OLE - Encaleret for ADH1 has a May 8, 2027 PDUFA date, with Priority Review, and the MAA is under EMA review with potential EU approval in the second half of 2027.

SEC original ↗Bridgebio Pharma, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

(Nasdaq BBIO) ( BridgeBio or the Company ), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today its financial results for the third quarter ended September 30, 2026, and provided an update on Attruby s commercial progress.

SEC original ↗Bridgebio Pharma, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

, and Australia New data to be shared at AHA 2026 BBP-418 for LGMD2I R9 PDUFA date set for November 27, 2026, with Priority Review U.

SEC original ↗Bridgebio Pharma, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Risks & headwinds

These forward-looking statements are based upon the current expectations and beliefs of the Company s management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

SEC original ↗Bridgebio Pharma, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

What changed vs prior quarter

Revenue — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Bridgebio Pharma, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Revenue — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Bridgebio Pharma, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Documents

Earnings deck slides

0 decks with slide view

Bridgebio Pharma, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

39 documents

Earnings releases

49 documents

Presentations

1 document

Transcripts

0 documents

No transcripts for Bridgebio Pharma, Inc. are held in this edition of the library.

See also the earnings calendar for every tracked company’s next earnings date.